Delirium in a patient with toxic flecainide plasma concentrations: The role of a pharmacokinetic drug interaction with paroxetine

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1366-1369

  Tsao, Yvonne Y ^a,d   Gugger, James J ^b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d Feinberg Pavilion LC 700 ^*  (United States)

Author keywords

Delirium; Flecainide; Paroxetine; Psychosis

Indexed keywords

CARVEDILOL; FLECAINIDE; FOLIC ACID; LEVOTHYROXINE; PANTOPRAZOLE; PAROXETINE; WARFARIN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DELIRIUM; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL;

AGED; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP2D6; DELIRIUM; DRUG INTERACTIONS; FEMALE; FLECAINIDE; HUMANS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 67651095953     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M067     Document Type: Article

References (13)

1. Latini R, Cavalli A, Maggioni AP, Volpi A. Flecainide distribution in human tissue. Br J Clin Pharmacol 1987;24:820-822
2. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med 1986;315:36-41.
3. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
4. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dosedependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine. Eur J Clin Pharmacol 1996;51:73-78 (Pubitemid 26300937)
5. Lim KS, Cho JY, Jang IJ, et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008;66:660-666
6. DeVane CL. Antidepressant-drug interactions are potentially but rarely clinically significant. Neuropsychopharmacology 2006;31:1594-1606
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
8. Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. J Clin Psychiatry 1999;60(suppl 8):4-10.
9. Drerup U. Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide. Dtsch Med Wschr 1988;113:386-388
10. Bennett MI. Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997;70:93-94
11. Ting SM, Lee D, Maclean D, Sheerin NS. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. Cardiology 2008;111:83-86
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245 (Pubitemid 11140804)
13. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-680 Epub 27 Mar 2007. DOI 10.1345/aph.1H423